ClinicalTrials.gg
CompletedNCT04674358Updated Mar 19, 2025Results posted

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

A Phase 2/3 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Vehicle Opthalmic Solution in Dry Eye and Dry Eye Syndromes, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
329
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.

Enrollment
4th of 11
329 · median 158
Started
2020
the only one that year
Phase 2/3
Only one
of the 11
Registered
3rd of 11
by date
Lead sponsor
11 of 11
Aldeyra Therapeutics, Inc.

Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 4th largest by enrollment, is the only one that started in 2020, is the only one in phase 2/3, and was the 3rd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About reproxalap

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing reproxalap in Dry Eye Syndromes as a file.
02

Study summary

The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease.

03

Conditions studied

  • Dry Eye
  • Dry Eye Syndromes

Browse trials for

Keywords

  • reproxalap
  • ADX-102
  • Tranquility
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age (either gender and any race);
  • Reported history of dry eye for at least 6 months prior to Visit 1;
  • Reported history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1

Exclusion criteria

Exclusion Criteria:

  • slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
  • Diagnosis of an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
  • Contact lens use within 7 days of Visit 1 or anticipate using contact lenses during the trial;
  • Eye drop use within 2 hours of Visit 1;
  • Previous laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Cyclosporine 0.05% or 0.09% or lifitegrast 5.0% ophthalmic solution use within 90 days of Visit 1;
  • Be receiving systemic therapy (not including inhaled corticosteroids) within 14 days of Visit 1 or anticipate such therapy throughout the study period;
  • Planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;
  • Temporary punctal plugs during the study that have not been stable within 30 days of Visit 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
329 participants (actual)

Study arms

  • Experimental
    Reproxalap Ophthalmic Solution (0.25%) administered QID over two consecutive days.

    Drug: Reproxalap Ophthalmic Solution (0.25%)

  • Placebo comparator
    Vehicle Ophthalmic Solution administered over two consecutive days.

    Drug: Vehicle Opthalmic Solution

Interventions

  • Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).

  • DrugVehicle Opthalmic Solution

    Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).

06

What researchers measure

Primary outcomes

  1. Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber

    Change from baseline comparison of reproxalap to vehicle for conjunctival redness on a 0 to 4 scale ( 0 = normal, 4 = prominent), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline included baseline, site, treatment group, and nominal time point as fixed effects.

    Time frame: The efficacy assessment period was assessed during the 90-minute dry eye chamber at Day 2; baseline was Pre-Dose #1 at Day 1.

Secondary outcomes

  1. Schirmer Test Change From Baseline After the First Dose on Day 1

    Change from baseline comparison of reproxalap to vehicle for Schirmer test on a millimeter line (0 = none, 35 = maximum), where a shorter length indicates a worse outcome. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline included baseline and treatment group as fixed effects.

    Time frame: The efficacy assessment period was before and after the final dose on Day 1; baseline was Pre-Dose #1 at Day 1.

07

Results

Posted Mar 19, 2025

Participant flow

Participant flow — Overall Study
MilestoneReproxalap Ophthalmic Solution (0.25%)Vehicle
Started164163
Completed162160
Not completed23

Outcome measures

PrimaryConjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber

Change from baseline comparison of reproxalap to vehicle for conjunctival redness on a 0 to 4 scale ( 0 = normal, 4 = prominent), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline included baseline, site, treatment group, and nominal time point as fixed effects.

Time frame:
The efficacy assessment period was assessed during the 90-minute dry eye chamber at Day 2; baseline was Pre-Dose #1 at Day 1.
Reported as:
Least squares mean · units on a scale
Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber
units on a scaleReproxalap Ophthalmic Solution (0.25%)Vehicle
Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber0.185 ± 0.02330.156 ± 0.0229
SecondarySchirmer Test Change From Baseline After the First Dose on Day 1

Change from baseline comparison of reproxalap to vehicle for Schirmer test on a millimeter line (0 = none, 35 = maximum), where a shorter length indicates a worse outcome. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline included baseline and treatment group as fixed effects.

Time frame:
The efficacy assessment period was before and after the final dose on Day 1; baseline was Pre-Dose #1 at Day 1.
Reported as:
Least squares mean · millimeters
Schirmer Test Change From Baseline After the First Dose on Day 1
millimetersReproxalap Ophthalmic Solution (0.25%)Vehicle
Schirmer Test Change From Baseline After the First Dose on Day 15.9 ± 0.533.5 ± 0.53
Post-hocConjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber Using Computer Automated Grading

Change from baseline comparison of reproxalap to vehicle for conjunctival redness on a 0 to 255 scale ( 0 = none, 255 = maximum), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline included baseline, site, treatment group, and nominal time point as fixed effects.

Time frame:
The efficacy assessment period was assessed during the 90-minute dry eye chamber at Day 2; baseline was Pre-Dose #1 at Day 1.
Reported as:
Least squares mean · units on a scale
Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber Using Computer Automated Grading
units on a scaleReproxalap Ophthalmic Solution (0.25%)Vehicle
Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber Using Computer Automated Grading0.309 ± 0.21600.962 ± 0.2121
Post-hocNumber of Subject Eyes That Are Schirmer Test Responders (Eyes 10 Millimeters or More Increase From Baseline)

The number of subject eyes that are schirmer test responders (eyes with 10 millimeters or more increase from baseline) using a millimeter line (0 = none, 35 = maximum), where a shorter length indicates a worse outcome.

Time frame:
Efficacy was assessed after a single dose on Day 1; baseline was assessed approximately two weeks before dosing.
Reported as:
Number · eyes
Number of Subject Eyes That Are Schirmer Test Responders (Eyes 10 Millimeters or More Increase From Baseline)
eyesReproxalap Ophthalmic Solution (0.25%)Vehicle
Number of Subject Eyes That Are Schirmer Test Responders (Eyes 10 Millimeters or More Increase From Baseline)12564
Statistical analysis
  • Reproxalap Ophthalmic Solution (0.25%) · Odds ratio (or): 2.63 · 95% CI 1.67 to 4.14

Adverse events

Collected over The period of time over which adverse events were collected for each subject in the clinical trial was approximately one week.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reproxalap Ophthalmic Solution (0.25%)0/164 (0%)0/164 (0%)118/164 (72%)
Vehicle0/163 (0%)0/163 (0%)2/163 (1.2%)
Most frequent other events
Most frequent other events
EventReproxalap Ophthalmic Solution (0.25%)Vehicle
General disorders and administration site conditionsGeneral disorders118/1642/163

Baseline characteristics

Safety population

Age, Categorical
Age, Categorical(Participants)Reproxalap Ophthalmic Solution (0.25%)VehicleTotal
<=18 years000
Between 18 and 65 years8782169
>=65 years7781158
Sex: Female, Male
Sex: Female, Male(Participants)Reproxalap Ophthalmic Solution (0.25%)VehicleTotal
Female118120238
Male464389
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Reproxalap Ophthalmic Solution (0.25%)VehicleTotal
Hispanic or Latino101222
Not Hispanic or Latino154151305
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Reproxalap Ophthalmic Solution (0.25%)VehicleTotal
American Indian or Alaska Native101
Asian121224
Black or African American182240
Native Hawaiian or Other Pacific Islander011
White132127259
Other000
Multiple112
Region of Enrollment
Region of Enrollment(participants)Reproxalap Ophthalmic Solution (0.25%)VehicleTotal
United States164163327
Iris Color (Right Eye)
Iris Color (Right Eye)(Participants)Reproxalap Ophthalmic Solution (0.25%)VehicleTotal
Black145
Blue484492
Brown7573148
Hazel241842
Green142337
Gray213
Other000
Iris Color (Left Eye)
Iris Color (Left Eye)(Participants)Reproxalap Ophthalmic Solution (0.25%)VehicleTotal
Black145
Blue484492
Brown7573148
Hazel241842
Green142337
Gray213
Other000
08

Study locations

1 site
  • University Clinical Health
    Memphis, Tennessee 38103, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Sep 2021, 9 months.

Results were first posted in Mar 2025, 3 years 6 months after primary completion.

Of 15 phase 2/3 interventional studies under Dry Eye Syndromes, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2020
First posted
Dec 19, 2020
StartActual
Nov 21, 2020
Primary completionActual
Sep 12, 2021
CompletionActual
Sep 12, 2021
Results first posted
Mar 19, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04674358
Responsible party
Sponsor
First posted
Dec 19, 2020
Start date
Nov 21, 2020
Primary completion
Sep 12, 2021
Completion
Sep 12, 2021
Results posted
Mar 19, 2025
Last update
Mar 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reproxalap

Start the discussion